Zomedica (ZOMDF) director adds 300,000 shares in open-market buys

Rhea-AI Filing Summary

Zomedica Corp. director Johnny D. Powers reported open-market purchases of company common stock. He bought a total of 300,000 shares in two transactions, acquiring 200,000 shares at $0.106 per share and 100,000 shares at $0.105 per share. These are direct holdings in non-derivative common stock.

Insider Trade Summary

Net Buyer: 300,000 shares ($31,700)

Net Buy 2 txns

Insider POWERS JOHNNY D

Role null

Bought 300,000 shs ($32K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, without par value	100,000	$0.105	$11K
Purchase	Common Stock, without par value	200,000	$0.106	$21K

Holdings After Transaction: Common Stock, without par value — 4,025,000 shares (Direct, null)

Footnotes (1)

Key Figures

First purchase: 200,000 shares at $0.106/share Second purchase: 100,000 shares at $0.105/share Total shares bought: 300,000 shares

3 metrics

First purchase 200,000 shares at $0.106/share Open-market buy of common stock, non-derivative

Second purchase 100,000 shares at $0.105/share Open-market buy of common stock, non-derivative

Total shares bought 300,000 shares Net buy across two open-market transactions

Key Terms

open-market purchase, Common Stock, without par value, non-derivative, Form 4

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock, without par value financial

"security_title": "Common Stock, without par value""

non-derivative financial

"transaction_type": "non-derivative""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POWERS JOHNNY D

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE

STE 100

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, without par value	05/12/2026		P		100,000	A	$0.105	4,025,000	D
Common Stock, without par value	05/13/2026		P		200,000	A	$0.106	4,225,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Johnny D. Powers	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Zomedica (ZOMDF) report in this Form 4?

Zomedica reported that director Johnny D. Powers made two open-market purchases of common stock. He acquired 200,000 shares at $0.106 per share and 100,000 shares at $0.105 per share, for a total of 300,000 shares of non-derivative common stock.

Who is the insider trading Zomedica (ZOMDF) shares in this filing?

The insider is Johnny D. Powers, a director of Zomedica Corp. The Form 4 shows he directly bought a combined 300,000 shares of common stock in open-market transactions, increasing his direct ownership position in the company’s non-derivative shares.

How many Zomedica (ZOMDF) shares did Johnny D. Powers buy?

Johnny D. Powers bought a total of 300,000 Zomedica common shares. The filing details purchases of 200,000 shares at $0.106 per share and 100,000 shares at $0.105 per share, all reported as direct, non-derivative open-market transactions.

At what prices were the Zomedica (ZOMDF) insider purchases made?

The insider purchases were made at $0.106 and $0.105 per share. Johnny D. Powers acquired 200,000 shares at $0.106 and 100,000 shares at $0.105 in open-market transactions, according to the Form 4 filed for Zomedica Corp.

Are the Zomedica (ZOMDF) insider purchases derivative or non-derivative?

The reported insider purchases are non-derivative common stock. Johnny D. Powers bought 300,000 shares of Zomedica’s common stock directly in open-market transactions, and the filing shows no associated derivative exercises or derivative positions in this report.